Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8683599 | 0.82 | MAPK1 (0.52) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19779407 | 0.81 | VNN1 (0.62) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8681274 | 0.81 | MAPK1 (0.49) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL186007 | 0.77 | HCAR3 (0.57) | HCAR3KDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL18173893 | 0.76 | HCAR3 (0.64) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL200701 | 0.76 | HDAC3 (0.41) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL19779334 | 0.76 | VNN1 (0.60) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16824371 | 0.75 | HCAR3 (0.55) | HCAR3HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL14677474 | 0.74 | CSNK2A1 (0.55) | HCAR3HCAR2CSNK2A1MAPK1 | |
| SCHEMBL10370009 | 0.74 | TDP1 (0.38) | HCAR3HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102414177-B | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-07-02 | — | — | CN | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010117662-A1 | MODULATORS OF S1P AND METHODS OF MAKING AND USING | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| US-5719187-A | Compounds having a guanidine structure and pharmaceutical composition containing same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 1998-02-17 | — | — | US | disclosed |
| EP-0572635-B1 | COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | CENTRE NAT RECH SCIENT (FR) | 1996-12-27 | — | — | EP | disclosed |
| US-5480884-A | Compounds having a guanidine structure | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1996-01-02 | — | — | US | disclosed |
| EP-0572635-A1 | NOVEL COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME. | CENTRE NAT RECH SCIENT (FR) | 1993-12-08 | — | — | EP | disclosed |
| EP-0572635-A4 | NOVEL COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME. | CENTRE NAT RECH SCIENT (FR) | 1993-09-17 | — | — | EP | disclosed |
| WO-1993010102-A1 | NOVEL COMPOUNDS HAVING A GUANIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) (FR) | 1993-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | HCAR3 302/4885HDAC3 1696/4885HDAC1 1428/4885 |
| US-20100249071-A1 | Modulators of S1P and Methods of Making And Using | S1PR5, S1PR1, S1PR2 | HCAR3 468/4885HDAC3 1582/4885HDAC1 1888/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | HCAR3 302/4885HDAC3 1696/4885HDAC1 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.